These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37697037)

  • 21. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C; Le K; Draves M; Seoane-Vazquez E
    JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Profile of Use of Rituximab in Tertiary Care Hospitals of Central India.
    Singh A; Sahoo AK; Biswal D; Sheth PG; Dhaneria S; Gupta D
    J Pharm Bioallied Sci; 2022; 14(4):191-195. PubMed ID: 37051423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The response rate of alternative treatments for drugs approved on the basis of response rate.
    Haslam A; Gill J; Prasad V
    Int J Cancer; 2021 Feb; 148(3):713-722. PubMed ID: 32700797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study.
    Ouimet C; Hutchinson N; Wang C; Matyka C; Del Paggio JC; Kimmelman J
    Sci Rep; 2023 Sep; 13(1):16138. PubMed ID: 37752147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
    Roskoski R
    Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis on the characteristics of targets with FDA approved drugs.
    Sakharkar MK; Li P; Zhong Z; Sakharkar KR
    Int J Biol Sci; 2007 Dec; 4(1):15-22. PubMed ID: 18167532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts.
    Bharate SS
    Int J Pharm; 2021 Sep; 607():120993. PubMed ID: 34390812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring anti-malarial potential of FDA approved drugs: an in silico approach.
    Ramakrishnan G; Chandra N; Srinivasan N
    Malar J; 2017 Jul; 16(1):290. PubMed ID: 28720135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
    Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.